SPEAKER AND PANELIST BIOGRAPHIES
Santa Ono, PhD, President and Vice-chancellor, UBC
Professor Ono is a professor of medicine and biology, Ono has worked at Harvard, Johns Hopkins, University College London, and Emory universities. He was also inducted by Johns Hopkins into its Society of Scholars, which honours former faculty who have gained distinction in their fields. His research encompasses the immune system, eye inflammation and age-related macular degeneration – a leading cause of blindness. Ono has been named a recipient of the 2016 National Association of Asian American Professionals (NAAAP) 100 award as one of the most influential leaders who have made significant contributions to their profession and the Asian community.
Pascal Spothelfer, President and CEO, Genome BC
Pascal holds a law degree and a PhD in law from the University of Basel, Switzerland and a Master of Business Administration from INSEAD in France. His previous positions include: Vice President Communications and Community Partnerships at the University of British Columbia, President and CEO of the British Columbia Technology Industry Association (BCTIA) and President and CEO of NovAtel Inc.
Gavin Stuart MD, Director, Life sciences BC; Vice-Provost Health, UBC
As Vice-Provost Health, Dr. Stuart plays a significant role in the provincial discourse and action around an academic health sciences network in BC. Prior to this, he served as Dean of the UBC Faculty of Medicine. His research expertise is in the areas of gynecologic cancer, including population-based screening programs and the conduct of clinical trials as therapeutic interventions in gynecologic cancer.
Sir Malcolm Grant, Chairman, National Health Services, England
Sir Malcolm Grant is the inaugural and current chairman of NHS England. Currently, the NHS is building partnerships with academia and industry to decode the human genome, in people with rare diseases and cancer, through the 100,000 Genomes Project, a ground breaking and world leading initiative.
Leroy Hood MD, PhD, VP & CSO, Providence St. Joseph Health; President, Institute for Systems Biology
Dr. Hood has made outstanding contributions to the advancement of biological sciences since the 1960s, including his involvement in the development of five instruments critical for contemporary biology¾automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. He has been a leader in the development of systems biology its linkage to personalized medicine, and is now pioneering new approaches to P4 medicine—predictive, preventive, personalized, and participatory.
Ida Goodreau, Board Director, Genome BC; Director Center for Healthcare Management
Ms. Goodreau is the former CEO of Vancouver Coastal Health, one of six regional health authorities in BC. She has extensive executive management experience in healthcare, forestry and natural gas, and has worked in New Zealand, Norway, Ontario and BC. She sits on the Boards of Fortis Inc., Fortis BC and Pharmasave National Pharmacies and is a past Director of the Vancouver Foundation, Vancouver Board of Trade and Women’s Leadership Circle.
Ian Rongve, Assistant Deputy Minister, BC Ministry of Health
Dr. Rongve was Assistant Professor of Economics at University of Regina, before joining public service in BC where he served as executive director for seven years and then went on to serve as assistant deputy minister of advanced, education, education and now health.
Verna Yiu, President and CEO, Alberta Health Services
Dr. Yiu is a Pediatric Nephrologist. She has played numerous leadership roles, both at the University of Alberta, and at Alberta Health Services, where she previously oversaw the integration and coordination of a diverse, complex, end-to-end health delivery model for the province.
Elizabeth Baca MD, MPA, Senior Health Advisor, Governor’s Office of Planning and Research, California
Dr. Baca is passionate about building healthy, resilient communities. In her current role, she is working across sectors to foster collaboration, elevate the connection between health and the built environment, and leading the effort to incorporate health considerations into the planning process. She is also engaged with several data initiatives to improve access to data to foster innovation in planning healthy, resilient communities.
David Snadden MB ChB, MCISc, MD, Senior Executive Dean Education, UBC Faculty of Medicine
Dr. Snadden establishes and communicates a vision for the UBC Faculty of Medicine’s educational programs. In his previous roles as Associate Dean, Northern Medical Program, and Regional Associate Dean, Northern BC, he worked in partnership with the University of Northern British Columbia and Northern Health Authority to develop and implement the Northern Medical Program and the expansion of postgraduate medical education in the north.
Joby McKenzie, Senior Vice President, Business Development, LifeLabs Genetics.
Dr. McKenzie holds a Bachelor of Science (Honours) in Molecular Biology and Biochemistry from Simon Fraser University; a Doctorate in Philosophy (PhD), Molecular and Medical Genetics, from the University of Toronto, and a Masters in Business Administration, with a specialization in health care from the Richard Ivey School of Business. She is responsible for overseeing and leading the implementation of LifeLabs Genetics business development strategy, and identifying opportunities for new product and service development to support long-term growth in new and existing markets.
Sonya Satveit, CEO and Founder, Open Source Health Inc.
Open Source Health is the first Precision Medicine Platform for Women’s Health. Sonya is passionate about putting Women’s Health at the forefront of the transformation of healthcare that is taking place.
Heather Davidson PhD, Assistant Deputy Minister, Planning Innovation Division, BC Ministry of Health
Dr. Davidson has worked with the B.C. provincial government since 1991, in a variety of roles with the Ministry of Health, Ministry of Housing and Constructive Standards, Ministry of Social Development. Her current responsibilities include strategic planning and policy for the health sector, performance monitoring and analytics, and health research.
Thomas Grogan MD, Pathologist, Professor Emeritus, University of Arizona; Founder and Senior Vice President, Ventana Medical Systems, Roche Group
1985, Dr. Grogan has been involved in evaluating the development of novel companion diagnostics, and assists with the establishment of strategic alliances and research collaborations to develop diagnostic tests for targeted therapies. He received a BA in Biology from the University of Virginia, and an MD from George Washington School of Medicine, subsequently completing a post doctorate fellowship in hematopathology at Stanford University.
Dr. Grogan is a professor Emeritus of Pathology at the University of Arizona’s College of Medicine, specializing in hematopathology. He is a founding member of the International Lymphoma Study Group, which was responsible for formulating the current WHO classification scheme for clinical practice. He has authored over 250 papers on lymphoma and myeloma, and holds patents for the kinetic-mode process for automated immunohistochemistry (IHC) and in-situ hybridization (ISH).
David Fajgenbaum MD, MBA, MSc, Co-Founder & Executive Director of the Castleman Disease Collaborative Network (CDCN)
Dr. Fajgenbaum, is an Assistant Professor of Medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania, the Co-Founder and Executive Director of the CDCN, and Associate Director, Patient Impact of the University of Pennsylvania’s Orphan Disease Center. He is a member of Forbes Magazine’s 2015 30 Under 30 Healthcare list.
Lisa Carver, Director of Stakeholder Relations, Michael Smith Foundation for Health Research
As Director, Stakeholder Relations, Lisa is responsible for the organization’s stakeholder and government relations strategy and building strong and effective relationships between MSFHR and key audiences. Lisa comes from a journalism and public affairs background. She began her career working as a reporter and producer for Vancouver’s CKNW and CBC Radio, and has over 15 years of experience in corporate and public affairs, including the Banff Centre, Vancouver Coastal Health and its Research Institute, and the global communications-marketing consultancy firm, Edelman. Lisa holds a Bachelor of Arts from the University of British Columbia, a post-diploma in broadcast journalism from the British Columbia Institute of Technology, and a certificate in knowledge translation from Sick Kids Hospital and University of Toronto.
Sasha Ottey, Founder and Executive Director of PCOS Challenge, Inc.
Ms. Ottey is a Clinical and Research Microbiologist with a Bachelor’s degree in Clinical Laboratory Science from Howard University and a Master’s in Health Administration from the University of Phoenix. In 2009, She started PCOS Challenge Inc., which now has over 9,000 members worldwide.
Rob Boushel D.Sc, Director, School of Kinesiology, The University of British Columbia
Dr. Boushel is an expert in exercise physiology with focus on cardiovascular and muscle metabolism and is the recipient of numerous awards and recognitions for research excellence and teaching in Canada and Scandinavia.
Brendan Byrne, Chief Innovation Officer, Telus Health
Dr. Byrne is well known as a physician and computing expert throughout North America. Brendan is passionate about the role that mobile and digital technology can play in improving healthcare outcomes in Canada. As CIO of Telus Health he leads Telus’ focus on continued digital innovation and the evolution of their health solutions to an open platform of products and services.
Carolyn Bell, Executive Director, Genetic Services Branch, Ministry of Health, Government of British Columbia
Carolyn has worked for various private, federal and provincial government agencies over the past twenty-five years. She has held senior and executive leadership roles in the BC Ministries of Government Services, Finance, Environment and Health. Her portfolios have included health benefits administration and overseeing one of BC’s largest outsourcing deals, strategic human resources, IM/IT project management, evaluation and provincial analytics services, stakeholder relations, policy and legislative development. She is currently the Executive Director, Genetic Services in the Hospital, Diagnostic and Clinical Services Division of the BC Ministry of Health. Under Ms. Bell’s leadership, the Ministry is working with stakeholders to create the vision and strategic direction for the current and future delivery of personalized medicine/genomics health care services in the province. Carolyn enjoys the complex, dynamic world of health strategy and welcomes the opportunity to exchange ideas with stakeholders and interdisciplinary partners. She has a Master of Public Administration and BA (Honours) in Economics
Jim Kean, founder Wellness Fx and General Manager of the Consumer Platform, Cambria Health
Jim Kean is a senior technology executive with an innovative career focused on developing disruptive consumer-oriented fitness, health, and wellness experiences. A digital health pioneer, 1995 he founded Sapient Health Network which became the consumer facing business of WebMD. He is the Founder and former CEO of WellnessFx™, a company that provides inexpensive, profile driven access to targeted health content, diagnostic and telehealth services, and HIPAA secure storage. Currently, Jim is the General Manager of the Consumer Platform for Cambia Health; a Blue Cross Blue Shield insurer based out of Portland, OR. In this capacity he is developing a next generation platform for omni-channel consumer engagement. The platform is data science driven and, among other things, is developing self evolving health accounts based on augmented intelligence and data aggregation.
Senator James S. Cowan, retired Canadian Senator
The Honorable James S. Cowan, QC is a Canadian lawyer, a senator from Nova Scotia from 2008 to 2017, Leader of the Opposition in the Senate from 2008 to 2015, and leader of the Independent Liberal caucus until June 15, 2016. He has been a partner at the legal firm of Stewart McKelvey since 1967. He is co-winner in 2016 of the annual advocacy award from the American Society of Human Genetics, cited for his role in pushing a law that would prevent genetic discrimination in Canada as the sponsor for new legislation that would bar employers and insurance companies from demanding genetic testing – or asking to see genetic test results.
Paul Drohan, Member Board of Directors, Aspect Biosystems, Global Sr.VP – Genzyme
Mr. Drohan is currently on the Board of Directors of Aspect Biosystems, an award-winning biotechnology company specializing in 3D bioprinting and tissue engineering. In addition, he is Principal at HBH Health consulting, and a Strategic Advisor to Cyon Therapeutics Inc., a clinical phase biotechnology company developing a novel therapeutics platform for the treatment of sepsis using anti-PCSK9. Mr. Drohan served as President and CEO of LifeSciences BC from 2013-2016.
John Mattick PhD, Executive Director, Lab Head- RNA Biology and Plasticity, Garvan Research
Institute of Medical Research
Prof. Mattick has made several seminal contributions to molecular biology, including the development of one of the first recombinant DNA-based vaccines. He has pioneered a new view of the genetic programming of humans, by showing that the majority of the genome, previously considered ‘junk’, specifies a dynamic network of regulatory RNAs that guide differentiation and development. He has served on councils, advisory boards and committees of a number of organizations, including Genome Canada, the Wellcome Trust, the Human Frontier Science Program, the National Health & Medical Research Council, and the Human Genome Organization.
Andrew Morris, Chief Scientist, Scottish Government Health Directorates, National Health Service, Scotland
Seconded as Chief Scientist at the Scottish Government Health Directorate, Dr. Morris is a Professor of Medicine, Director of the Usher Institute of Population Health Sciences and Informatics, and Vice Principal of Data Science at the University of Edinburgh. His research interests relate to the application of informatics to study the epidemiological and molecular etiological basis of diabetes and its complications.
Martin Dawes MBBS, MD, FRCGP, Head, Department of Family Practice, UBC
Dr. Dawes is a Royal Canadian Legion Professor, with expertise and research interests in the areas of information retrieval, hypertension, and pharmacogenomics in primary care. He is CEO and President of GenXys, founded to implement pharmacogenetics into primary care.
Paul Terry PhD, President and CEO, PHEMI
PHEMI is a big data warehouse company that lets organizations easily access and mine any variety of data at any volume to drive insights that lower costs, improve outcomes, and allow better decisions faster. In addition to his leadership role at PHEMI, Dr. Terry is a member of the Boards of Directors of Providence Health Care, Genome BC, and Life sciences BC.
David Wishart PhD, Professor, Department of Biological Sciences and Computing Science, University of Alberta
Dr. Wishart has active research programs in structural biology, nanobiology, synthetic biology, prion biology, bioinformatics and metabolomics. Dr. Wishart led the Human Metabolome Project (HMP), a multi-university, multi-investigator project that catalogued all the known metabolites. This information has been archived on the freely accessible Human Metabolome Database.
Raymond Ng PhD, Professor, Computer Science, UBC
Dr. Raymond Ng is internationally renowned for his data mining research. He is also part-time Chief Informatics Officer of the PROOF Centre of Excellence for the Prevention of Organ Failure.
Jamie Sawchuk, Lead, Innovation Practices, Deloitte
Mr. Sawchuk is the BC Lead on Deloitte’s National Innovation, Disruption and Exponential Technologies Council and a member of Deloitte’s Global Innovation Leadership team. He has worked with both domestic and international health and life sciences clients to develop and implement break-through strategies and innovative new business models.
Gane Ka-Shu Wong, Associate Director, Bejing Genomics Institute, Professor of Medicine and Biological Sciences, University of Alberta
Gane Ka-Shu Wong, is a founding member of two internationally renowned DNA/RNA sequencing organizations, initially at the University of Washington and subsequently in China. The latter, BGI, is a world leader in genomics research and clinical diagnostics. More recently, they developed their own sequencing platform (BGISEQ-500) for use in precision medicine. Dr. Wong is also Professor of Medicine and Biological Sciences at the University of Alberta. (BGI), Regional Manager, BGI Americas Corporation
Aditya Pai, Associate Partner, IBM Watson Health Group
Mr. Pai is a Healthcare and Life Sciences Transformation expert with the IBM Watson Group with seventeen years of health care and life sciences expertise as a clinician and senior management consultant. His interests encompass genomic and precision medicine and their role in health care.
Gordon McCauley, President & CEO, The Centre for Drug Research and Discovery (CDRD)
Mr. McCauley has held several leadership roles in national companies including Viable Healthworks, Allon Therapeutics and is Co-Founder and Partner of NDI Capital. In addition to his role at CDRD, he is a is a Director of Defender Therapeutics, 3D Signatures, BioteCanada and LifeSciences British Columbia. He has served in a staff capacity for two Prime Ministers and a former Ontario Premier.
Joyce Drohan, Healthcare Practice Lead in BC, PricewaterhouseCoopers
Ms. Drohan has over 20 years of experience in end-to-end large-scale transformation in the public and private sectors. Her main areas of expertise include healthcare transformation, innovation, and sustainability, which deliver significant cost savings with improved patient services in complex, multi-stakeholder environments. She has worked with some of the largest organizations in the world such as the UK Department of Health, NHS UK, The BBC, AstraZeneca UK, AstraZeneca Canada, Pfizer Canada, and LifeLabs among others.
Julio Montaner OC, OBC, MD, FRCPC, FCCP, Director of the British Columbia Centre for Excellence in HIV/AIDS; Director of IDC, and Physician Program Director for HIV/AIDS Providence Health Care
Dr. Montaner is a world leader in HIV/AIDS research. He has received numerous awards and distinctions for his research work, and is a member of the Order of British Columbia, and an Officer of The Order of Canada. He has been inducted into the Royal Society of Canada-The Academies of Arts, Humanities and Sciences, and into the Canadian Medical Hall of Fame.
Pieter Cullis PhD, Director, Life Sciences Institute, UBC
Dr. Cullis is a Professor at the Department of Biochemistry and Molecular Biology at UBC. He is an internationally recognized pioneer and leader in the field of lipids, biological membranes and liposomal drug delivery systems. He has been very active in the development of several biotechnology companies and is recognized as a remarkable researcher and innovator, with over 300 publications and 40 patents. He is a winner of the 2011 Prix Galien, and is member of the Royal Society of Canada.
Bruce McManus MD, PhD, FRSC, FCAHS, FRCPC, FCAP, FACC, Professor, Department of Pathology and Laboratory Medicine, at UBC
Dr. McManus is the CEO for Centre of Excellence for Prevention of Organ Failure (PROOF Centre), and Co-Director of the Institute for Heart + Lung Health. He has been recognized for his scientific contributions through various prestigious awards including the Max Planck Research Award, BC Innovation Council’s Lieutenant Governor’s Technology Innovation Award, and the Lifetime Achievement Award from Canadian Blood Services, among many others. He was elected as a Fellow of the Academy of Sciences, Royal Society of Canada, and as an inaugural Fellow of the Canadian Academy of Health Sciences.
Howard Lim MD, PhD, Program Director, Medical Oncology, BC Cancer Agency
As a Medical Oncologist, Dr. Lim specializes in gastrointestinal cancer. He uses pathology tumor banks and sequencing technology for an improved understanding of tumor biology and methods of detection that are cost effective.
Rob Fraser PhD, CEO, Molecular You Corporation; Co-Founder, Personalized Medicine Initiative (PMI)
Dr. Fraser has a strong background and success rate in the development of targeted therapeutics. Prior to joining Molecular You Corp., he co-founded the PMI with Dr. Pieter Cullis. He has previously worked as the Group Leader in Target Identification for Sanofi, Senior Director of Biology for Xenon Pharmaceuticals, Senior Director of Pharmacology and Site Director at Neuromed (now Zalicus), and Director Project Evaluation at the Centre for Drug Research and Development (CDRD).
Catalina Lopez-Correa MD, PhD, Chief Scientific Officer and Vice President, Sector Development, Genome BC
Dr. Lopez-Correa has nearly two decades of international experience in the academic and private sectors. Prior to Genome BC, she was the Vice-President and CSO, Scientific Affairs, at Genome Quebec.
Louise Turner, Advisory Board Member, Premier’s Technology Council (PTC), BC
The PTC reports directly to the Premier of BC, recommending policies and programs to build BC’s knowledge economy and support the growth of technology and knowledge-based companies. Previously, Ms. Turner has worked with the British Government and the EU, as well as high tech start-up companies and not for profit organizations in BC, where she led a three-year national policy initiative to enhance economic development in Western Canada through the growth of life science and medical device companies. She is also on the board of the Rick Hansen Foundation.
Simon Pimstone, President and CEO, Xenon Pharmaceuticals
Dr. Pimstone is a founder, Director, and President and Chief Executive Officer at Xenon Pharmaceuticals Inc., a privately owned biotechnology company engaged in discovering and developing novel pharmaceuticals targeting genes and proteins that underlie human diseases. He received his MD from the University of Cape Town and his PhD through the University of Amsterdam. He is an internal medicine specialist (FRCPC) with an interest in cardiovascular disease. Dr. Pimstone has served as a consultant physician at the St. Paul’s Hospital Lipid Clinic in Vancouver. He is currently the Chairman of the Providence Healthcare Research Institute, and he serves as a Director on the Board of Life Sciences British Columbia. In 2005 he received the Business in Vancouver Top 40 under 40 Award and in 2004 the Globe & Mail’s Canadian Top 40 Under 40 Award.
Dermot Kelleher, Dean of Medicine, University of British Columbia
Dr. Kelleher joined UBC in 2015 as Dean of the Faculty of Medicine. Prior to his appointment at UBC, Dr. Kelleher served as Vice-President Health and Dean of the Faculty of Medicine at Imperial College London, where he also held a concurrent appointment as Dean of the Lee Kong Chian Medical School in Singapore until 2014. Dr. Kelleher has also served as Head of the School of Medicine and Vice Provost for Medical Affairs at Trinity College, Dublin, and President of the Federation of European Academies of Medicine. Dr. Kelleher graduated from medicine from Trinity College Dublin in 1978, going on to specialize in gastroenterology and the immune response to many of the leading causes of gastrointestinal infectious disease worldwide. He has received many prestigious awards including a Fogarty Scholarship at the University of California San Diego, Wellcome Senior Fellow in Clinical Science, and most recently the Conway Medal from the Royal Academy of Medicine in Ireland. Dr. Kelleher has worked to found several companies supporting both translational developments in biomedical science and fostering collaboration in biomedical research in both Dublin and London.
André Galarneau, MSc PhD Director Medical Affairs – Oncology, Merck Canada
Dr. André Galarneau was appointed Director Medical Affairs, Oncology at Merck Canada in May 2017. He is responsible for the company’s team of Oncology medical and scientific experts. Prior to this role, he held the positions of Director Medical Affairs in Neurosciences and Medical Advisor in oncology and neurosciences at Merck Canada since 2010. Native of Montreal, André began his career as an Alzheimer’s disease researcher before joining Schering-Plough in 2008 as a medical & scientific liaison. He published in various peer reviews journal through his career in different field of expertise including neuroscience, oncology and anesthesia. André holds a Bachelor of Science degree and a Master of Science degree, both in biochemistry from Université de Montréal. He also obtained a PhD in experimental medicine from McGill University in Montréal.